M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX.
Ceccherini, F., Falciani, C., Onori, M., Scali, S., Pollini, S., Rossolini, G.M., et al. (2016). Antimicrobial activity of levofloxacin - M33 peptide conjugation or combination. MEDCHEMCOMM, 7(2), 258-262 [10.1039/c5md00392j].
Antimicrobial activity of levofloxacin - M33 peptide conjugation or combination
FALCIANI, CHIARA;ONORI, MARTINA;SCALI, SILVIA;BRACCI, LUISA;PINI, ALESSANDRO
2016-01-01
Abstract
M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1007168
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo